KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Ionis Pharmaceuticals (IONS) EBIAT (2016 - 2025)

Ionis Pharmaceuticals has reported EBIAT over the past 17 years, most recently at -$229.4 million for Q4 2025.

  • Quarterly results put EBIAT at -$229.4 million for Q4 2025, down 119.83% from a year ago — trailing twelve months through Dec 2025 was -$381.4 million (up 15.97% YoY), and the annual figure for FY2025 was -$381.4 million, up 15.97%.
  • EBIAT for Q4 2025 was -$229.4 million at Ionis Pharmaceuticals, down from -$128.6 million in the prior quarter.
  • Over the last five years, EBIAT for IONS hit a ceiling of $224.6 million in Q4 2021 and a floor of -$229.4 million in Q4 2025.
  • Median EBIAT over the past 5 years was -$87.6 million (2021), compared with a mean of -$75.0 million.
  • Biggest five-year swings in EBIAT: skyrocketed 361.22% in 2021 and later plummeted 1026.51% in 2024.
  • Ionis Pharmaceuticals' EBIAT stood at $224.6 million in 2021, then crashed by 123.34% to -$52.4 million in 2022, then surged by 82.33% to -$9.3 million in 2023, then plummeted by 1026.51% to -$104.3 million in 2024, then crashed by 119.83% to -$229.4 million in 2025.
  • The last three reported values for EBIAT were -$229.4 million (Q4 2025), -$128.6 million (Q3 2025), and $123.6 million (Q2 2025) per Business Quant data.